BSEM (BioStem Technologies) EBITDA per Share: $0.42 (TTM As of Sep. 2025)


BSEM BioStem Technologies Inc BSEM
49 GF Score
Price $3.24
GF Value $141.65
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is BioStem Technologies EBITDA per Share?

BioStem Technologies BSEM +0.62% 49 EBITDA per Share is $0.42 as of Sep. 2025. GuruFocus rates BSEM with a GF Score™ of 49/100 and a GF Value™ of $141.65 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,140 Biotechnology companies, BioStem Technologies ranks worse than 87719.21% on this metric.

BioStem Technologies's EBITDA per Share for the three months ended in Sep. 2025 was $0.07. Its EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2025 was $0.42.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for BioStem Technologies's EBITDA per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of BioStem Technologies was 75.50% per year. The lowest was -68.00% per year. And the median was 23.20% per year.

BSEM's 3-Year EBITDA Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 15.05
* Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.

BioStem Technologies's EBITDA for the three months ended in Sep. 2025 was $1.5 Mil.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of BioStem Technologies was 56.40% per year. The lowest was -191.20% per year. And the median was -21.30% per year.


BioStem Technologies  (OTCPK:BSEM) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


BioStem Technologies EBITDA per Share Related Terms


BioStem Technologies EBITDA per Share Historical Data

* Premium members only.

The historical data trend for BioStem Technologies's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioStem Technologies EBITDA per Share Chart

BioStem Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.15 -0.05 -0.57 -0.55 1.45

BioStem Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Sep21 Dec21 Mar22 Sep22 Dec22 Mar23 Sep23 Dec23 Sep24 Dec24 Sep25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.10 -0.01 0.44 0.35 0.07
BSEM
49GF Score
BioStem Technologies Inc BSEM
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioStem Technologies EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

BioStem Technologies's EBITDA per Share for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA per Share(A: Dec. 2024 )
=EBITDA/Shares Outstanding (Diluted Average)
=31.494/21.698
=1.45

BioStem Technologies's EBITDA per Share for the quarter that ended in Sep. 2025 is calculated as

EBITDA per Share(Q: Sep. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=1.506/23.235
=0.06

EBITDA per Share for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $0.42 mean?
BioStem Technologies (BSEM) has a EBITDA per Share of $0.42 as of Sep. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #999999 out of 1140 companies in the Biotechnology industry.
Is BioStem Technologies' EBITDA per Share too high?
BioStem Technologies' current EBITDA per Share is $0.42. The Biotechnology industry median EBITDA per Share is 15.05. BioStem Technologies' value of $0.42 is 97.2% below this industry median. Based on the distribution chart, BioStem Technologies ranks #999999 out of 1140 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' EBITDA per Share compare to XLO and TCRX?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #999999 out of 1140 companies for EBITDA per Share. This places BioStem Technologies in the lower half of its industry. The industry median EBITDA per Share is 15.05. BioStem Technologies' value of $0.42 is 97.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Biotechnology company?
The median EBITDA per Share among Biotechnology companies is 15.05, based on 1,140 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioStem Technologies's current EBITDA per Share of $0.42 is 97.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on BioStem Technologies and its competitors. For the Biotechnology industry, the median EBITDA per Share is 15.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioStem Technologies's current EBITDA per Share is $0.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $141.65, compared to a current price of $3.24 — trading 97.7% below its estimated fair value. The current EBITDA per Share is $0.42 and 97.2% below the Biotechnology industry median of 15.05. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current EBITDA per Share is $0.42 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioStem Technologies (BSEM) Overvalued in 2026?

Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued. The current stock price of $3.24 is trading 97.7% below its estimated GF Value™ of $141.65. GuruFocus considers BioStem Technologies to be Possible Value Trap.

Key valuation signals for BSEM:

  • EBITDA per Share: $0.42
  • GF Value™: $141.65 vs. price of $3.24 (97.7% below fair value)
  • GF Score™: 49/100 with 3 warning signs
  • Industry Position: 97.2% below the Biotechnology median (#999999 of 1140)

No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BioStem Technologies Business Description

Address 2836 Center Port Circle, Pompano Beach, FL, USA, 33064
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score

Get the complete analysis for BSEM

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.24
Price
$141.65
GF Value